Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO and Co-Founder Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit. The presentation is part of the CEO Spotlight event scheduled for Aug. 26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia. The summit, which runs Aug. 25-26, brings together leaders across biotechnology, medical technology, research, manufacturing and investment.
The announcement is significant because it places Nutriband at the forefront of the life sciences community, offering a platform to showcase its lead product under development: an abuse-deterrent fentanyl patch incorporating its AVERSA™ technology. This technology is designed to incorporate aversive agents into transdermal patches, aiming to prevent abuse, diversion, misuse and accidental exposure involving drugs with abuse potential. The potential implications are substantial, as the opioid crisis continues to challenge public health, and innovative solutions like AVERSA could play a critical role in mitigating risks associated with potent pain medications.
Sheridan's participation in the CEO Spotlight event suggests that Nutriband is gaining recognition among industry peers and investors. The summit is a key gathering for the life sciences sector in Georgia, a state that has become a hub for biotech and medical technology innovation. By presenting at this event, Nutriband can attract potential partners, investors and collaborators who are interested in addressing critical healthcare challenges.
According to the press release, Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The AVERSA technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This broad applicability could position the company as a leader in abuse-deterrent formulations, a market segment with growing demand due to regulatory and societal pressures.
The company’s website is www.nutriband.com. For more information about Nutriband and its latest news, visit their newsroom at https://ibn.fm/NTRB. The full press release can be viewed at https://ibn.fm/Un3ax.
The 2026 Georgia Life Sciences Summit provides an ideal venue for Nutriband to highlight its progress and future plans. As the company continues to develop its AVERSA technology, its participation in such events underscores its commitment to addressing the opioid epidemic and improving patient safety. The presentation at the summit is not just a routine conference appearance; it is a strategic move to solidify Nutriband's position in the life sciences ecosystem and to communicate its value proposition to a wider audience.
